Cancer Research UK and Sosei Heptares sign agreement to

HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies...

Related Keywords

United Kingdom ,Japan ,Tokyo ,Cambridge ,Cambridgeshire ,London ,City Of ,Eleanor Perkin ,Frazer Hall ,Neurocrine Biosciences ,Sosei Heptares ,Hironoshin Nomura ,Candelle Chong ,Matt Barnes ,Genentech Roche ,Ellie Bennett ,Nigel Blackburn ,Shinichiro Nishishita ,Sosei Heptare ,Sosei Group Corporation ,Linkedin ,Twitter ,Medicinal Chemistry Gordon Research Conference ,Good Laboratory Practice ,Novartis ,Pfizer ,Youtube ,Astrazeneca ,Sosei Group ,Cancer Research United Kingdom ,Sosei Group Corporation The Company ,Facebook ,Tokyo Stock Exchange ,Medistrava Consulting For International Media ,Group Corporation ,Clinical Trial ,Licence Agreement ,Drug Development ,Heptares Therapeutics ,Chemistry Gordon Research Conference ,Clinical Trial Authorisation ,Investigational Medicinal ,Microsatellite Stable ,Research United Kingdom ,Cancer Research United Kingdom Centre ,Chief Financial Officer ,International Media ,